Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Imaging Perfusion Restrictions from Extracellular Solid Stress - ImPRESS
2023-507575-22-00Phase 2Authorised
- Sponsor
- Oslo University Hospital
- Start
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of losartan in glioblastoma (GBM) and non-small cell lung cancer (NSCLC) (3 arms), sponsored by Oslo University Hospital. Planned start Sep 2024; status: authorised.
02
Drugs
losartan
03
Conditions
glioblastoma (GBM)non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2023-507575-22-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-507575-22-00.